Alvesco
(Ciclesonide)ApprovedSmall molecule
Ciclesonide is an inhaled steroid used to prevent asthma symptoms and reduce inflammation in the airways. It can also be used as a nasal spray to treat allergy symptoms and nasal inflammation.[2] Alvesco is currently approved and in use across 9 indications[4].[1]
Alvesco is one of 151 small molecule programs targeting Respiratory System Disease. It is currently in Approved.
9
Indications
55
Total Trials
0
Active Trials
150
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Alvesco
AAzurity Pharmaceuticals
Approved
Rayaldee
OOrganon and Co
Preclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Statins
SanofiPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Calcium
Eli LillyPreclinical
Olokizumab
UCBPreclinical
Conventional
PPopulation Health Research Institute
Preclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Moderna COVID-19 Vaccine
ModernaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Asthma27 trials
Show 24 more trials
Allergic Rhinitis8 trials
Show 5 more trials
Seasonal Allergic Rhinitis7 trials
COVID-194 trials
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
Completed·—·Phase 2/3·NCT04870333·2,240 enrolled
Inhaled Ciclesonide for Outpatients With COVID19
Terminated·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2/3·NCT04435795·215 enrolled
7 more indications
Patient Preference1 trial
Systemic1 trial
Tics1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Oct 20, 2006
OMNARIS
NDA NDA022004
Jan 10, 2008
ALVESCO
NDA NDA021658
Jan 20, 2012
ZETONNA
NDA NDA202129
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Alvesco drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ciclesonide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Glucocorticoid Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- AAzurity Pharmaceuticals
Patent Landscape[6]
Patent Cliff
Feb 1, 2028
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8371292Feb 1, 2028